Objectives We aimed to investigate the association between the albumin-corrected anion gap (ACAG) and the prognosis of cardiogenic shock (CS). Design A multicentre retrospective cohort study. Setting Data were collected from the Medical Information Mart for Intensive Care (MIMIC-IV) and eICU Collaborative Research Database (eICU-CRD) datasets. Participants 808 and 700 individuals from the MIMIC-IV and eICU-CRD, respectively, who were diagnosed with CS. Primary and secondary outcomes The primary endpoint was short-term all-cause mortality, including intensive care unit (ICU), in-hospital and 28-day mortality. The secondary endpoints were the 28-day free from the ICU duration and the length of ICU stay. Results CS patients were divided into two groups according to the admission ACAG value: the normal ACAG group (≤20 mmol/L) and the high ACAG group (> 20 mmol/L). CS patients with higher ACAG values exhibited increased short-term all-cause mortality rates, including ICU mortality (MIMIC-IV cohort: adjusted HR: 1.43, 95% CI=1.05–1.93, p=0.022; eICU-CRD cohort: adjusted HR: 1.38, 95% CI=1.02–1.86, p=0.036), in-hospital mortality (MIMIC-IV cohort: adjusted HR: 1.31, 95% CI=1.01–1.71, p=0.03; eICU-CRD cohort: adjusted HR: 1.47, 95% CI=1.12–1.94, p=0.006) and 28-day mortality (adjusted HR: 1.42, 95% CI: 1.11 to 1.83, p=0.007). A positive linear correlation was observed between the ACAG value and short-term mortality rates via restricted cubic splines. Compared with the AG, the ACAG presented a larger area under the curve for short-term mortality prediction. In addition, the duration of intensive care was longer, whereas the 28-day free from the ICU duration was shorter in patients with a higher ACAG value in both cohorts. Conclusion The ACAG value was independently and strongly associated with the prognosis of patients with CS, indicating that the ACAG value is superior to the conventional AG value.
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide; hypertension is one of the most important risk factors for AF and contributes to both its initiation and maintenance. This study investigated the contribution of enolase 1 (ENO1) to hypertension-associated atrial remodeling and susceptibility to pacing-induced AF. Long-term hypertension was associated with increased AF inducibility in rats, and atrial transcriptomic analyses at two stages of hypertension identified persistent ENO1 upregulation. ENO1 was also increased in two external human left atrial AF datasets. An angiotensin II (Ang II)-induced atrial cardiomyocyte injury model was constructed to evaluate the role of ENO1 in Ang II-induced cardiomyocyte hypertrophy. In Ang II-stimulated primary neonatal rat atrial cardiomyocytes, siRNA-mediated ENO1 knockdown attenuated hypertrophic and oxidative-stress-related changes and was accompanied by lower PI3K/AKT phosphorylation and NADPH oxidase 4 (NOX4) expression. AP-III-a4 treatment produced concordant changes in selected cellular endpoints. PI3K inhibition reduced NOX4 expression and intracellular hydrogen peroxide levels. In ENO1-silenced cardiomyocytes, PI3K activation with 740Y-P partially increased both PI3K/AKT phosphorylation and NOX4 expression. In Ang II-infused hypertensive mice, AP-III-a4 treatment reduced atrial enlargement, fibrosis, PI3K/AKT phosphorylation, NOX4 expression, and atrial reactive oxygen species signals; it also attenuated atrial effective refractory period shortening. AP-III-a4 significantly shortened the duration of pacing-induced AF and was associated with numerically lower AF inducibility, although the latter difference did not reach statistical significance. Collectively, these findings support the involvement of PI3K/AKT signaling in ENO1-associated regulation of NOX4 and suggest that this relationship may contribute to the observed attenuation of hypertension-associated atrial remodeling.